R. E. Millikan

724 total citations
13 papers, 595 citations indexed

About

R. E. Millikan is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, R. E. Millikan has authored 13 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in R. E. Millikan's work include Prostate Cancer Treatment and Research (6 papers), Renal cell carcinoma treatment (3 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). R. E. Millikan is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Renal cell carcinoma treatment (3 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). R. E. Millikan collaborates with scholars based in United States and Spain. R. E. Millikan's co-authors include Xifeng Wu, Colin P. Dinney, Jian Gu, H. Barton Grossman, Maosheng Huang, Qing Zhang, Margaret R. Spitz, Carol J. Etzel, Christopher I. Amos and Lance C. Pagliaro and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

R. E. Millikan

13 papers receiving 588 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. E. Millikan United States	7	302	187	182	135	124	13	595
Jason B. Litten United States	9	202 0.7×	73 0.4×	132 0.7×	87 0.6×	87 0.7×	21	537
Kian Fong Foo Singapore	13	141 0.5×	193 1.0×	320 1.8×	238 1.8×	74 0.6×	24	712
E. E. Holdener Switzerland	10	255 0.8×	48 0.3×	187 1.0×	128 0.9×	117 0.9×	16	611
V. Papadimitrakopoulou United States	13	223 0.7×	53 0.3×	313 1.7×	304 2.3×	110 0.9×	41	606
M Fukushima Japan	9	159 0.5×	99 0.5×	341 1.9×	238 1.8×	49 0.4×	37	639
Myla Lai-Goldman United States	10	146 0.5×	69 0.4×	255 1.4×	94 0.7×	115 0.9×	14	473
Bernie Fitzharris United Kingdom	10	111 0.4×	129 0.7×	236 1.3×	72 0.5×	74 0.6×	11	474
Omar Alhalabi United States	12	115 0.4×	191 1.0×	242 1.3×	161 1.2×	71 0.6×	102	604
Sophie Barrett United Kingdom	9	256 0.8×	68 0.4×	295 1.6×	54 0.4×	161 1.3×	18	660
Oyewale O. Abidoye United States	13	143 0.5×	158 0.8×	451 2.5×	221 1.6×	77 0.6×	24	657

Countries citing papers authored by R. E. Millikan

Since Specialization

Citations

This map shows the geographic impact of R. E. Millikan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. E. Millikan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. E. Millikan more than expected).

Fields of papers citing papers by R. E. Millikan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. E. Millikan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. E. Millikan. The network helps show where R. E. Millikan may publish in the future.

Co-authorship network of co-authors of R. E. Millikan

This figure shows the co-authorship network connecting the top 25 collaborators of R. E. Millikan. A scholar is included among the top collaborators of R. E. Millikan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. E. Millikan. R. E. Millikan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Aparicio, Ana M., Andrea Harzstark, Emile N.J.T. van Lin, et al.. (2011). Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP).. Journal of Clinical Oncology. 29(15_suppl). 4666–4666. 3 indexed citations

2.

Montero, Alberto J., C. Marcela Díaz‐Montero, R. E. Millikan, et al.. (2009). Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-α: association of pretreatment serum levels with survival. Annals of Oncology. 20(10). 1682–1687. 28 indexed citations

3.

Millikan, R. E., C. Logothetis, & Peter F. Thall. (2008). Response:Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. JNCI Journal of the National Cancer Institute. 100(9). 682–683. 1 indexed citations

4.

Logothetis, Christopher J., Lance C. Pagliaro, Sijin Wen, et al.. (2007). Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. JNCI Journal of the National Cancer Institute. 99(21). 1613–1622. 46 indexed citations

5.

Wu, Xifeng, Jian Gu, H. Barton Grossman, et al.. (2006). Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell-Cycle–Control Genes. The American Journal of Human Genetics. 78(3). 464–479. 230 indexed citations

6.

Leibovici, Dan, H. Barton Grossman, Colin P. Dinney, et al.. (2005). Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival. Journal of Clinical Oncology. 23(24). 5746–5756. 131 indexed citations

7.

Millikan, R. E., Peter F. Thall, Lance C. Pagliaro, et al.. (2004). Randomized, adaptive, phase II selection trial of four chemotherapy regimens in androgen independent prostate cancer (AIPC). Journal of Clinical Oncology. 22(14_suppl). 4561–4561. 1 indexed citations

8.

Siefker‐Radtke, Arlene O., et al.. (2004). Implementation of a novel statistical design to evaluate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M. D. Anderson Cancer Center. Journal of Clinical Oncology. 22(14_suppl). 4543–4543. 1 indexed citations

9.

Tannir, Nizar M., X. Wang, Chaan S. Ng, et al.. (2004). A randomized phase III Trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). Journal of Clinical Oncology. 22(14_suppl). 4607–4607. 1 indexed citations

10.

Tannir, Nizar M., X. Wang, Chaan S. Ng, et al.. (2004). A randomized phase III Trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). Journal of Clinical Oncology. 22(14_suppl). 4607–4607. 1 indexed citations

11.

Takikawa, Yasuhiro, Hideyuki Miyoshi, Christian Rust, et al.. (2001). The bile acid–activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes. Gastroenterology. 120(7). 1810–1817. 67 indexed citations

12.

Tu, Shi‐Ming, Lance C. Pagliaro, R. J. Amato, et al.. (1998). Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.. PubMed. 4(5). 1193–201. 19 indexed citations

13.

Ellerhorst, Julie A., Shi‐Ming Tu, R. J. Amato, et al.. (1997). Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.. PubMed. 3(12 Pt 1). 2371–6. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact